TrialESMO open2025

A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer.

M A Gouda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.